RecruitingNot ApplicableNCT03729115
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
Chicago Alternative Prevention Study for Diverse Populations of High Risk Women
Sponsor
University of Chicago
Enrollment
400 participants
Start Date
May 30, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
This study is aimed to establish a registry of women undergoing intensive surveillance for the early detection of breast cancer in high-risk women.
Eligibility
Sex: FEMALEMin Age: 25 Years
Plain Language Summary
Simplified for easier understanding
This trial is studying an enhanced screening program using multiple imaging methods to detect breast cancer early in women who are at very high risk for developing the disease due to genetic mutations or other risk factors.
**You may be eligible if...**
- You carry a known high-risk gene mutation (such as BRCA1, BRCA2, TP53, PALB2, PTEN, CDH1, or STK11)
- Your lifetime risk of breast cancer is 30% or higher based on genetic and non-genetic risk scores
- Your 5-year risk of breast cancer is 6% or higher (for women aged 40–64 or 65+)
- Women 65+ may also qualify with dense breast tissue and a lifetime risk of 20% or more
- You are female and have not had breast cancer
**You may NOT be eligible if...**
- You have a personal history of breast cancer
- You do not meet the high-risk genetic or statistical criteria above
- You are unable to undergo MRI or other imaging
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREMagnetic Resonance Imaging (MRI)
Patients will have MRI scans every 6 months.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03729115
Related Trials
Genomic Services Research Program
NCT025959571 location
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT050002941 location
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT0587057925 locations
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT0624799533 locations
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
NCT072251141 location